Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer (COROS)

Santa Chiara Hospital

Status: Enrolling

Conditions: BRCA Mutation; Prostate Cancer; Castrate Resistant Prostate Cancer

Treatments: Drug: Olaparib

Study type: Observational

Funder types: Other

Identifiers

NCT06783127

A809

Details and patient eligibility

About

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Enrollment: 3,000 estimated patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice

Exclusion criteria

Olaparib treatment in a clinical trial

Trial design

3,000 participants in 1 patient group

mCRPC treated with olaparib

Description:

mCRPC patients who receive olaparib in daily clinical practice

Treatment:

Drug: Olaparib